Coverage Guide
Medicare GLP-1 Bridge Program (2026): $50 a Month, and the Trap to Avoid
Compiled from Medicare and CMS publications • Last reviewed August 5, 2026
Executive Summary
For most of the GLP-1 era, Medicare did not cover these drugs for weight loss at all. That changed on July 1, 2026. Eligible Part D beneficiaries can now get certain FDA-approved GLP-1 medications for $50 a month regardless of income, under a program CMS has said will run through December 31, 2027.
If you qualify, this is the cheapest route to an FDA-approved GLP-1 that exists — cheaper than every cash-pay program on this site, including compounded ones. It also contains one specific trap around Zepbound formats that is easy to fall into and expensive to get wrong. Both are covered below.
Section 1: What Is Covered
| Medication | Covered form | Notes |
|---|---|---|
| Foundayo (orforglipron) | Tablet | The once-daily oral GLP-1 that launched in the U.S. in January 2026. |
| Wegovy (semaglutide) | Injection or tablet | Both formats are covered, which gives you a choice between pen and pill. |
| Zepbound (tirzepatide) | KwikPen only | Single-dose vials and pens are NOT covered. See Section 4. |
Section 2: Who Qualifies
You must meet all of the baseline requirements, plus one of the two clinical criteria, measured when you start GLP-1 therapy.
Baseline requirements
Aged 18 or older.
Enrolled in a Medicare Part D prescription drug plan.
Prescribed a covered GLP-1 drug for weight loss and weight maintenance.
Using the medication as part of a lifestyle program focused on diet and exercise, certified by your provider.
Clinical criteria — meet one
BMI of 35 or higher, on its own.
BMI of 30 or higher together with certain qualifying health conditions.
The qualifying condition list is set by the program. Ask your provider or plan which conditions count for your situation, since this determines eligibility at the 30–34.9 BMI range.
Section 3: How to Get It
Step 1: Talk to your provider
Start with whoever manages your care. Medicare's own guidance is to talk with your health care provider if you think you may be eligible. You do not need a specialist telehealth service to access the program.
Step 2: Your provider sends the prescription
It must be for a covered drug in a covered form, sent to your pharmacy. Getting the Zepbound format right matters here.
Step 3: Your provider completes the attestation
When requested, your provider must submit the required form, and must certify that you are using the medication as part of a lifestyle program focused on diet and exercise.
Step 4: The pharmacy processes it
Your pharmacy may ask for your Medicare Number or the last four digits of your Social Security Number. Comparing mail-order pharmacy costs is worthwhile — Medicare notes mail order is sometimes cheaper.
Step 5: If you have no prescriber, use a telehealth partner
Eli Lilly maintains a list of independent telehealth providers that can support eligible Medicare Part D patients in accessing treatment through the Bridge. Published copays across those partners range from roughly $10 to $100 for the visit side, depending on the provider and your coverage.
Section 4: The Zepbound Format Trap
KwikPen is covered. Single-dose vials are not.
Medicare covers Zepbound under the Bridge as the KwikPen only. The program does not cover single-dose Zepbound vials or pens. This is easy to get wrong for a specific reason: the single-dose vial is the format Eli Lilly promotes hardest on the self-pay side, at $299 a month for the 2.5 mg starting dose through LillyDirect. Most of the coverage you will read about “cheap Zepbound” is about those vials.
- !If you are eligible for the Bridge, make sure your prescription specifies the KwikPen, not a vial.
- !A vial prescription will not be covered at $50 — you would be paying LillyDirect self-pay pricing instead, six times the Bridge price at the starting dose and roughly nine times at higher doses.
- !If Zepbound KwikPen does not suit you, Wegovy is covered in both injection and tablet form, and Foundayo is covered as a tablet.
Section 5: How $50 Compares
Against the cheapest routes reviewed on this site, for an eligible Medicare beneficiary the Bridge is not close.
| # | Provider | Rating | Monthly medication cost | Why it ranks here |
|---|---|---|---|---|
| 1 | NovoCare PharmacyCheapest brand-name cash-pay | 9.1 | From $149/mo | Wegovy and Ozempic tablets from $149/month — three times the Bridge price for the same class of approved medication. |
| 2 | LillyDirectCheapest brand-name tirzepatide | 9.2 | From $299/mo | Zepbound single-dose vials from $299/month, rising to roughly $449 at higher doses. Note this is the format the Bridge excludes. |
| 3 | Cora HealthCheapest compounded | 9 | $99/mo | $99/month all-inclusive, but compounded medications are not FDA-approved and the FDA has documented specific quality concerns in this category. |
| 4 | Walgreens Weight ManagementSurfaces the Bridge directly | 8.7 | $50/mo via Bridge | Promotes the Medicare GLP-1 Bridge at $50/month alongside $49 clinician visits. The $50 covers medication only — visit costs are separate. |
| 5 | KlinicAccepts Medicare directly | 7.8 | Insurance-based; verified before your consultation | One of very few telehealth platforms accepting Medicare and Medicaid for both consultations and prescriptions. |
Prices are what each provider published as of the review date and change frequently. Confirm current pricing on the provider's own site before enrolling.
Frequently Asked Questions
What is the Medicare GLP-1 Bridge program?
A Medicare program that began July 1, 2026 giving eligible Part D beneficiaries access to certain FDA-approved GLP-1 drugs for weight management at $50 per month, regardless of income. CMS has said the program will be extended through December 31, 2027.
Which GLP-1 drugs does Medicare cover under the Bridge?
Per Medicare.gov: Foundayo (tablet), Wegovy (injection or tablet), and Zepbound — but Zepbound is covered as the KwikPen only. The program does not cover single-dose Zepbound vials or pens. That exclusion catches people out, because the single-dose vial is exactly the format LillyDirect sells at its lowest self-pay price.
Who qualifies for the $50 price?
You must be 18 or older, enrolled in a Medicare Part D plan, and meet the clinical criteria when you start GLP-1 therapy — a BMI of 35 or higher, or a BMI of 30 or higher together with certain qualifying health conditions. The $50 monthly cost applies regardless of your income level.
What does my doctor have to do?
Your provider must send a prescription for a covered GLP-1 drug to the pharmacy and, when requested, complete the required attestation. Your provider must also certify that you are using the GLP-1 as part of a lifestyle program focused on diet and exercise. Your pharmacy may ask for your Medicare Number or the last four digits of your Social Security Number to process the prescription.
Is $50 a month better than paying cash?
Substantially, if you qualify. The nearest cash-pay comparison for an FDA-approved drug is $149 a month for Wegovy or Ozempic tablets through NovoCare Pharmacy, or $299 for the lowest Zepbound vial dose through LillyDirect. Compounded programs start around $99 but supply a product the FDA has not reviewed. At $50 for an approved medication, the Bridge is the best value available to anyone eligible.